

SUPPLEMENTAL FIGURES AND TABLES

Contents

Appendix 1. Desensitization Response Criteria.....	2
Supplemental Table 1. HLA specificities assessed in circulating memory B cells and bone-marrow plasma cells with the HLA-specific B-cell Fluorospot in each patient.....	4
Supplemental Table 2. Summary of safety by cohort.....	6
Supplemental Table 3. Summary of pharmacokinetics of isatuximab by cohort after the first administration at a dose of 10 mg/kg.....	7
Supplemental Table 4. Summary of number of anti-HLA-antibody with baseline MFI ≥ 3000 reduced to < 2000 as measured in a SAB assay (using central laboratory assessment).....	8
Supplemental Table 5. Summary of pharmacodynamic changes from baseline to post-treatment	9
Supplemental Figure 1. Examples of responder patients per protocol who met all 3 criteria...	10
Supplemental Figure 2. Examples of responder patients per protocol that did not meet target cPRA in Criterion 1.....	12
Supplemental Figure 3. Examples of non-responder patients per protocol that met 0 of 3 criteria.....	14
Supplemental Figure 4. Representative images of mBCs and bone-marrow plasma HLA-sp fluorospot before and after treatment.....	16

Appendix 1. Desensitization Response Criteria

The target cPRA (ie, reduction of cPRA required to achieve at least 100% increase in likelihood of compatible donor [LCD]) is calculated according to the following equation (Kransdorf EP et al. Hum Immunol 2017;78(3):252-6). Examples of target cPRA reduction are presented in Table A.

$$LCD = 1 \text{ in } \frac{1}{1 - cPRA}$$

Table A. Examples of target cPRA reduction.

Baseline		Target	
cPRA	LCD	cPRA	LCD
99.99%	1:10000	99.98%	1:5000
99.90%	1:1000	99.80%	1:500
99.80%	1:500	99.60%	1:250
99.60%	1:250	99.20%	1:125
99.50%	1:200	99.00%	1:100
99.00%	1:100	98.00%	1:50
97.50%	1:40	95.00%	1:20
95.00%	1:20	90.00%	1:10
90.00%	1:10	80.00%	1:5
80.00%	1:5	60.00%	1:2.5

Abbreviations: cPRA, calculated panel reactive antibodies; LCD, likelihood of compatible donor.

Participants with baseline cPRA 100.00% were assigned with cPRA 99.99% for computational purpose.

Antibody titer is defined as the last dilution of serum at which positive results is obtained (eg, MFI ≥ 2000) (Tambur AR, et al. Hum Immunol 2016;77(8):624-30). Examples of antibody titer based on MFI are illustrated in Table B below.

Table B. Examples of antibody titer.

	Neat serum	1:2	1:4	1:8	1:16	1:32	Titer
Antigen 1 MFI	13430	12492	6250	3123	1550	790	8
Antigen 2 MFI	18320	20820	10501	5206	2604	1302	16
Antigen 3 MFI	11020	5493	2750	1384	688	360	4

Abbreviations: MFI, mean fluorescence intensity.

Using similar concept, Table D illustrates an example in which the second predefined desensitization criterion (ie, $\geq 75\%$ reduction in antibody titer from baseline to achieve target cPRA, see Table C) may be met. In this example, participant's baseline cPRA is measured by SAB as 97.50%, the target cPRA is therefore 95.00% as defined in Table A. Through serial dilution of the serum collected at baseline, titer required to achieve target cPRA is 16 (ie, achieved at 1:16 dilution). Subsequent post-treatment serum is therefore diluted at 1:4 (ie, 75% reduction from 1:16) to determine whether target cPRA is achieved. At Cycle 3 Day 1, target cPRA is reached at 1:4 dilution therefore meeting the aforementioned predefined desensitization criterion.

Table C. 75% reduction in antibody titer from baseline

Baseline		75% reduction	
Titer	Dilution	Titer	Dilution
2	1:2	1	Neat
4	1:4	1	Neat
8	1:8	2	1:2
16	1:16	4	1:4
32	1:32	8	1:8
64	1:64	16	1:16
128	1:128	32	1:32
256	1:256	64	1:64
512	1:512	128	1:128

Table D. Example of $\geq 75\%$ reduction in antibody titer from baseline to achieve target cPRA

	Neat serum	1:2 Titer=2	1:4 Titer=4	1:8 Titer=8	1:16 Titer=16	Response criterion met
Baseline cPRA	97.50%	97.50%	97.50%	96.00%	95.00% (target cPRA)	
C2D1 cPRA	96.00%		96.00%			No
C3D1 cPRA	96.00%		95.00% (target cPRA)			Yes

Abbreviations: C2D1, cycle 2 day 1; C3D1, cycle 3 day 1; cPRA, calculated panel reactive antibodies.

Supplemental Table 1. HLA specificities assessed in circulating memory B cells and bone-marrow plasma cells with the HLA-specific B-cell Fluorospot in each patient

Patient ID	HLA specificities	Patient ID	HLA specificities
Circulating HLA-specific memory B cells		Bone marrow-residing HLA-specific Plasma cells	
712	A*23:01	712	A*24:02
712	A*24:02	712	A*24:03
713	A*03:01	712	A*34:02
713	A*11:01	712	DRB1*14:01
713	B*07:02	712	DRB3*02:02
713	DRB1*01:03	712	DRB3*03:01
713	DRB1*11:04	714	A*68:02
714	A*02:01	714	B*37:01
714	B*57:01	714	B*67:01
714	DRB1*01:01	714	DQB1*03:02 DQA1*02:01
714	DRB1*04:02	714	DRB1*01:02
714	DRB1*07:01	714	DRB1*04:01
714	DRB1*10:01	714	DRB1*07:01
714	DRB1*11:01	714	DRB1*10:01
716	A*36:01	714	DRB1*15:01
717	A*01:01	714	DRB4*01:03
717	A*03:01	714	DRB5*02:02
717	A*24:02	724	B*27:05
717	A*29:02		
717	A*80:01		
717	B*07:02		
717	B*15:03		
717	B*15:12		
717	B*44:02		
717	B*45:01		
717	B*55:01		
717	DQB1*05:02/DQA1*01:02		
717	DQB1*06:03/DQA1*01:03		
717	DQB1*02:01/DQA1*02:01		
717	DQB1*02:02/DQA1*02:01		

717	DQB1*04:01/DQA1*02:01
717	DQB1*02:01/DQA1*03:01
717	DQB1*04:02/DQA1*04:01
718	A*01:01
718	A*23:01
718	A*24:02
718	A*36:01
718	B*57:01
718	DRB1*10:01
718	DRB1*15:03
719	A*01:01
719	A*36:01
719	DQB1*03:02/DQA1*02:01
719	DQB1*04:01/DQA1*02:01
719	DQB1*03:01/DQA1*06:01
722	A*23:01
722	B*07:02
722	B*51:01
722	DQB1*05:02/DQA1*01:02
722	DQB1*06:02/DQA1*01:02
723	DRB1*04:04
723	DRB3*03:01
724	A*02:01
724	A*11:01
724	A*68:01
724	B*27:05
724	B*37:01
724	DQB1*02:01 /DQA1*02:01
724	DQB1*02:01 /DQA1*03:01
724	DRB3*02:02

Supplemental Table 2. Summary of safety by cohort

n (%)	Cohort A (n=12)		Cohort B (n=11)	
	All grades	Grade ≥3	All grades	Grade ≥3
Any event	3 (25.0)	0	4 (36.4)	0
Infusion-related reaction	2 (16.7)	0	3 (27.3)	0
Nasopharyngitis	1 (8.3)	0	0	0
Headache	1 (8.3)	0	0	0
Tachycardia	1 (8.3)	0	0	0
Nasal congestion	1 (8.3)	0	0	0
Nausea	1 (8.3)	0	0	0
Myalgia	1 (8.3)	0	0	0
Temporomandibular Joint Syndrome	1 (8.3)	0	0	0
Chills	1 (8.3)	0	0	0
COVID-19	0	0	1 (9.1)	0

COVID-19, coronavirus disease.

Supplemental Table 3. Summary of pharmacokinetics of isatuximab by cohort after the first administration at a dose of 10 mg/kg

Mean $\pm$ SD [CV%]	Cohort A (n=11)	Cohort B (n=11)
$C_{\max}$ ($\mu\text{g/mL}$)	295 $\pm$ 128 [43]	285 $\pm$ 94 [33]
$t_{\max}^*$ (h)	3.67 (2.00–6.03)	3.40 (2.25–4.63)
$AUC_{1 \text{ week}}$ ($\mu\text{g}\cdot\text{h/mL}$)	29400 $\pm$ 7400 [25] [†]	20000 $\pm$ 5240 [26] [†]

*Median (min–max), $t_{\max}$ was generally at end of infusion

[†]n=10

$AUC_{1 \text{ week}}$, area under the curve over 1 week; $C_{\max}$, maximum plasma concentration; CV, coefficient of variation; SD, standard deviation; $t_{\max}$, time to reach maximal concentration

Supplemental Table 4. Summary of number of anti-HLA-antibody with baseline MFI ≥ 3000 reduced to < 2000 as measured in a SAB assay (using central laboratory assessment)

	Cohort A (n=12)	Cohort B (n=11)	All (N=23)
Maximum number of anti-HLA-antibody reduced [n (%)]			
Number of participants assessed	12	11	23
None	2 (16.7)	2 (18.2)	4 (17.4)
1-5	4 (33.3)	4 (36.4)	8 (34.8)
>5-10	4 (33.3)	4 (36.4)	8 (34.8)
>10-15	1 (8.3)	0	1 (4.3)
>15	1 (8.3)	1 (9.1)	2 (8.7)
Baseline MFI 3000<6000			
None	2 (16.7)	2 (18.2)	4 (17.4)
1-5	5 (41.7)	5 (45.5)	10 (43.5)
>5-10	3 (25.0)	3 (27.3)	6 (26.1)
>10-15	1 (8.3)	0	1 (4.3)
>15	1 (8.3)	1 (9.1)	2 (8.7)
Baseline MFI 6000<10000			
None	9 (75.0)	9 (81.8)	18 (78.3)
1-5	3 (25.0)	1 (9.1)	4 (17.4)
>5-10	0	1 (9.1)	1 (4.3)
>10-15	0	0	0
>15	0	0	0
Baseline MFI ≥ 10000			
None	12 (100)	11 (100)	23 (100)

Supplemental Table 5. Summary of statistical testing in pharmacodynamic changes from baseline to post-treatment

Biomarker	C3D1	C3D1 (p-value)	C3D1 (adjusted p-value)	FUP (Week 17)	FUP Week 17 (p-value)	FUP (Week 17) adjusted p-value
Treg cells (cells/ μ L)	13	0.889	1.000	10	0.557	1.000
Treg cells, CD38+ (cells/ μ L)	13	0.004	0.046	10	0.221	1.000
Treg cells, CD38- (cells/ μ L)	13	0.376	1.000	10	0.275	1.000
Plasma cells (cells/mL)	14	0.078	0.706	12	0.380	1.000
Plasmablasts (cells/mL)	14	0.025	0.245	12	0.791	1.000
Immunoglobulin G (g/L)	20	<0.001	<0.001	16	<0.001	<0.001
Immunoglobulin M (g/L)	20	<0.001	0.001	16	0.002	0.022
NK cells, CD38- (cells/ μ L)	13	0.085	1.000	10	0.200	1.000
NK cells, CD38+ (cells/ μ L)	13	<0.001	0.005	10	0.232	1.000
NK cells (cells/ μ L)	13	<0.001	0.005	10	0.275	1.000
Memory B-cell CD38+ (cells/mL)	16	0.083	0.706	N/A	N/A	N/A
Memory B-cell CD38- (cells/mL)	16	0.006	0.069	N/A	N/A	N/A

Supplemental Figure 1. Examples of responder patients per protocol who met all 3 criteria; (A) Antibody titration heat map, Plots of MFI change in anti-HLA antibody levels for antibodies with (B) baseline MFI of 3000 to <1000, and (C) baseline MFI ≥ 10000

A.

Class I

Class II

Patient 0837

Reduction
Observed in
Neat Serum
Over Time


Patient 8310

Reduction
Observed in
Neat Serum
Over Time


HLA on Bead	Neat			1:16			1:256			MFI
	BL	WK9	WK25	BL	WK9	WK25	BL	WK9	WK25	
A*01:01	14494	12307	10161	4217	2189	1726	408	125	45	
B*08:01	14422	7894	5923	3917	1243	926	329	16	0	
A*02:01	13626	16911	15572	2639	3030	2747	280	322	258	
A*02:03	12689	19327	15169	2428	2740	2602	213	284	222	
A*02:06	13801	14736	13766	2607	2640	2531	237	228	170	
A*11:02	11342	8459	9148	1608	1094	906	64	0	56	27
A*34:01	8759	8652	7361	1126	1073	847	0	56	27	
A*36:01	8384	6801	4862	1331	797	581	101	65	46	
A*68:01	10980	13500	13079	1735	2166	2089	153	218	175	
A*69:02	10051	10992	10076	1599	1636	1489	90	50	23	
A*69:01	10558	12292	11799	1596	2005	1904	95	162	109	
B*59:01	8694	3886	2224	1746	522	299	69	22	0	
A*03:01	7005	8214	4577	839	561	428	58	9	0	
A*11:01	7044	7619	5830	802	763	606	59	74	46	
A*29:01	6215	5575	3965	607	479	342	0	0	0	
A*29:02	7197	5688	3953	647	452	308	0	0	0	
A*31:01	6613	6204	4739	675	552	423	0	0	0	
A*33:01	5862	5781	4575	658	521	428	0	0	0	
A*34:02	7356	6434	4995	696	648	503	0	59	35	
A*56:01	6949	6164	4703	651	629	519	0	38	18	
A*56:02	7035	5960	5410	696	714	555	0	6	0	
A*74:01	7460	6729	5757	852	747	572	58	65	39	
A*80:01	7084	5364	3844	566	412	287	0	0	0	
B*13:02	5397	3033	2788	781	286	255	0	0	0	
B*46:01	4156	2182	1810	703	213	132	0	0	0	
A*33:03	6940	6793	5415	752	664	538	53	62	35	
A*26:01	5483	4523	3540	492	368	292	0	0	0	

HLA on Bead	Neat			1:16			1:256			MFI
	BL	WK9	WK25	BL	WK9	WK25	BL	WK9	WK25	
DQA1*05:01 DQB1*02:01	28878	29954	29290	22635	22061	20533	8423	5716	4549	>20,000
DQA1*02:01 DQB1*02:01	15276	20519	19279	12804	10947	9339	2666	1696	1430	10,000-20,000
DQA1*03:01 DQB1*02:01	22429	25827	24707	15766	13962	12745	3528	2357	1860	
DQA1*04:01 DQB1*02:01	20154	21151	19630	15925	11997	10786	3309	1702	1422	
DQA1*02:01 DQB1*02:02	17867	19932	18707	12266	11665	9767	2566	1612	1498	5000-9999
DQA1*05:03 DQB1*03:01	14918	14016	12192	5422	4115	3105	564	319	203	
DQA1*05:05 DQB1*03:01	14100	13668	12346	5119	3973	2912	461	290	168	2500-4999
DQA1*06:01 DQB1*03:01	13406	10811	9346	3458	2130	1565	240	124	62	
DQA1*01:01 DQB1*05:01	8419	9524	4678	1320	684	478	102	0	0	1000-2499
DRB1*15:02	8305	6298	5359	1460	749	563	128	23	0	
DRB1*15:03	8279	6666	5627	1434	846	573	140	26	7	
DRB3*01:01	7730	3637	2420	1248	283	140	81	0	0	
DRB5*02:02	7716	4796	3698	1246	517	326	103	0	0	
DQA1*04:01 DQB1*04:02	6681	5456	5066	1833	1316	960	163	52	16	
DRB7*01:01	6910	2216	1189	965	116	11	74	0	0	
DPA1*01:03 DPB1*02:01	4420	1296	646	525	46	0	13	0	0	
DRB1*03:01	4572	1976	1517	579	128	69	47	0	0	
DRB1*03:02	4579	1846	1385	558	120	59	3	0	0	
DRB1*09:01	4047	2550	1746	416	160	70	0	0	0	
DRB1*12:02	3750	1089	517	399	37	0	1	0	0	
DQA1*01:02 DQB1*05:02	2654	1801	1526	616	302	232	9	12	4	
DQA1*03:01 DPB1*04:02	3210	948	440	386	0	0	23	0	0	
DPA1*01:03 DPB1*28:01	3590	1143	545	431	21	0	6	0	0	
DQA1*01:05 DPB1*28:01	3706	987	501	456	4	0	0	0	0	
DRB1*07:01	3176	964	433	231	2	0	0	0	0	
DRB1*09:02	2057	1514	1271	223	104	61	0	0	0	

B.




C.




C, cycle; D, day; FUP, follow-up; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; N, neat; WK, week.

Supplemental Figure 2. Examples of responder patients per protocol that did not meet target cPRA in Criterion 1; (A) Antibody titration heat map, (B and C) plots of MFI change in anti-HLA levels for (B) antibodies with baseline MFI of 3000 to <1000, and (C) baseline MFI ≥10000


A.



B.



C.



C, cycle; D, day; FUP, follow-up; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; WK, week.

Supplemental Figure 3. Examples of non-responder patients per protocol that met 0 of 3 criteria; (A) Antibody titration heat map and (B and C) plots of MFI change in anti-HLA antibody levels for antibodies with (B) baseline MFI of 3000 to <1000, and (C) baseline MFI ≥ 10000

A.

Class I

HLA on Bead	Neat			1:16			1:256		
	BL	WK3	WK25	BL	WK3	WK25	BL	WK3	WK25
A*01:01	20682	27601	27291	18964	26103	26337	5412	9795	7084
A*23:01	20667	27201	26595	15189	22046	19524	2943	5486	3392
A*24:02	17483	26667	24224	13494	21047	18189	2509	5280	3354
A*30:01	20334	28548	27875	17366	22126	19789	3477	5663	3756
A*80:01	24658	27282	26613	15706	16742	16276	2816	4137	2780
B*13:02	20864	25695	23225	15338	14776	11587	2425	2556	1516
B*15:01	20431	27979	26121	15239	18678	15366	2789	3447	2316
B*15:02	19604	26784	24524	14107	16004	13543	2413	3163	1843
B*15:03	21671	28090	27193	15250	18225	14943	2656	3772	2186
B*16:12	20999	27999	27730	19143	23576	21344	4478	6020	4366
B*17:02	17877	25544	23763	12272	16495	13346	2441	3215	2008
B*35:01	18373	26582	25609	13962	18504	15321	2526	3652	2516
B*44:02	20809	27461	25729	16103	19525	16536	2960	4164	2832
B*44:03	21110	27424	26177	18071	20230	16408	3962	4533	2846
B*45:01	20993	27287	26435	18033	20513	17545	3888	4633	2929
B*49:01	21632	28896	27071	19640	22241	19175	4079	5299	3426
B*50:01	20822	27234	26258	17845	19347	16185	3317	4370	2615
B*51:01	21152	26216	27555	18402	22263	19686	4256	5779	3763
B*51:02	20506	26881	25413	18789	20556	17853	4510	5668	3607
B*52:01	17028	26935	23891	12932	18068	15703	2493	4348	2667
B*53:01	17471	26527	24487	13391	18524	16575	2826	4313	2577
B*78:01	20469	26995	25290	15891	18616	15675	2596	3936	2433
A*29:02	18435	24803	22535	9393	12514	9713	1194	1751	1001
B*15:10	19454	25788	23480	11750	14405	11896	1828	2532	1399
B*15:16	18275	27372	25816	12971	15414	12630	1967	2725	1503
B*18:01	20143	26512	25152	12881	15727	12544	1773	2686	1584

No Marked
Reduction
Observed
Over Time

Class II

HLA on Bead	Neat			1:16			1:256		
	BL	WK3	WK25	BL	WK3	WK25	BL	WK3	WK25
DRB1*13:03	24602	27456	26195	15742	19349	14772	2117	3268	2156
DRB1*16:01	24562	27505	27265	15318	17389	15368	2221	3539	2219
DRB1*16:02	24296	26649	26155	15983	15977	14623	2205	3393	2056
DRB1*01:03	20846	24520	24166	11502	12512	11491	1328	2273	1388
DRB1*04:02	21238	22453	21236	11573	11940	10111	1289	2103	1265
DRB1*08:01	19888	24568	23120	11168	14221	12175	1328	2731	1651
DRB1*11:04	23266	23565	22027	14314	13434	11625	1800	2571	1643
DRB1*11:04	23230	24963	23643	13744	14768	13204	1964	3066	1899
DRB1*12:01	21932	20750	19650	10331	9056	7463	1099	1297	791
DRB1*12:02	24006	24608	23076	13619	12566	11112	1598	2386	1385
DRB1*13:01	25221	27008	26275	14060	15940	13639	1846	3182	2032
DRB1*15:01	22584	24012	21899	12037	11288	9705	1355	1979	1146
DRB1*15:02	22568	25055	23677	11908	12424	10236	1399	2131	1311
DRB1*15:03	22941	24398	23071	11488	12280	9430	1291	2053	1223
DRB1*01:01	24201	26144	24466	12596	13243	11655	1431	2225	1352
DRB1*03:01	17208	18721	17183	7743	6872	5157	782	895	484
DRB1*03:02	18332	19247	18765	7216	7092	5612	527	524	514
DRB1*04:01	15502	20360	18319	7171	6846	5450	453	843	462
DRB1*04:04	19300	20097	17653	7141	6570	4942	530	812	414
DRB1*04:03	18620	19580	18616	6193	5591	4372	437	640	334
DRB1*14:01	21528	21323	19904	9716	9057	7452	930	1307	732
DRB1*14:02	17009	19507	17164	7675	7279	5726	721	919	496
DRB1*14:54	20988	21670	19402	8886	8688	6784	638	1177	646
DRB1*01:01	18128	18829	17010	7213	7213	5621	652	912	514
DRB1*02:02	16448	19548	17136	6190	5424	5135	456	646	284
DRB1*03:01	22927	23121	20779	10002	9053	7322	899	1223	664
DRB1*04:05	15279	16745	15192	5187	5548	4291	371	630	311

Patient 0832

No Marked
Reduction
Observed
Over Time

HLA on Bead	Neat			1:16			1:256		
	BL	WK3	WK25	BL	WK3	WK25	BL	WK3	WK25
A*01:01	8	0	0	0	0	0	0	0	0
A*02:01	70	0	50	15	0	1	0	0	0
A*02:03	45	0	41	9	0	14	0	0	0
A*02:06	59	0	32	0	0	0	0	0	0
A*03:01	0	0	0	0	0	0	0	0	0
A*11:01	2	0	0	0	0	0	0	0	0
A*11:02	0	0	0	0	0	0	0	0	0
A*23:01	10	0	0	0	0	0	0	0	0
A*24:02	11	0	0	0	0	0	0	0	0
A*24:03	40	0	0	0	0	0	0	0	0
A*25:01	219	213	449	12	0	0	0	0	0
A*25:01	0	0	0	0	0	0	0	0	0
A*29:01	389	282	370	173	236	133	6	0	0
B*27:05	116	16	40	1	0	0	0	0	0
A*29:02	282	150	237	116	110	21	0	0	0
A*30:01	45	0	5	0	0	0	0	0	0
A*30:02	39	0	0	0	0	0	0	0	0
A*31:01	18	0	0	0	0	0	0	0	0
A*32:01	63	0	20	6	0	0	0	0	0
A*33:01	23	0	0	0	0	0	0	0	0
A*34:01	0	0	0	0	0	0	0	0	0
A*34:02	2	0	7	0	0	0	0	0	0
A*36:01	31	0	8	0	0	0	0	0	0
A*43:01	0	0	0	0	0	0	0	0	0
A*66:01	0	0	0	0	0	0	0	0	0
A*66:02	0	0	0	0	0	0	0	0	0
A*68:01	42	0	13	2	0	0	9	0	1

HLA on Bead	Neat			1:16			1:256		
	BL	WK3	WK25	BL	WK3	WK25	BL	WK3	WK25
DRB1*01:01	6681	7016	6055	894	736	540	85	18	0
DRB1*01:02	6206	7835	6301	874	771	532	102	10	0
DRB1*04:01	6122	7430	6195	865	817	584	68	34	0
DRB1*04:04	6370	7371	6539	830	843	577	64	12	0
DRB1*14:02	5677	6783	5954	761	737	516	87	27	0
DRB1*15:01	5884	7193	5717	768	888	554	45	4	0
DRB1*15:02	5505	8027	6757	801	981	664	82	35	0
DRB1*15:03	5880	8185	6826	900	1016	690	97	42	0
DRB1*16:01	5562	7811	7103	977	1164	909	94	19	0
DRB1*16:02	5740	7146	5727	965	903	590	89	27	0
DRB1*04:05	4192	5554	4850	563	566	394	45	0	0
DRB1*04:03	4259	5522	4444	488	512	347	7	0	0
DRB1*03:01	4023	5905	4687	456	473	261	16	0	0
DRB1*01:01	4059	5263	4490	475	398	196	0	0	0
DRB1*02:02	4245	5315	4304	551	482	338	38	0	0
DRB1*01:03	3357	5393	4046	359	448	258	4	0	0
DRB1*03:01	2640	3740	3037	296	292	170	27	0	0
DRB1*03:02	2681	3655	2923	237	315	186	0	0	0
DRB1*04:02	3213	4825	3844	376	424	258	27	0	0
DRB1*08:01	2580	4602	3819	252	444	266	0	0	0
DRB1*09:01	2994	5560	3982	260	456	243	0	0	0
DRB1*09:02	3397	4781	3608	359	428	254	22	0	0
DRB1*10:01	2806	4297	3309	291	381	199	10	0	0
DRB1*11:01	3079	3601	2725	335	347	217	6	5	0
DRB1*11:04	2774	3863	3060	323	376	251	6	11	0
DRB1*12:01	2983	3994	3082	313	332	174	0	0	0
DRB1*12:02	3502	4844	3887	375	451	278	5	0	0

B.

	Class I	Class II
Patient 0811 No Marked Reduction Observed Over Time	Baseline MFI 3000 to <10000 	Baseline MFI 3000 to <10000
Patient 0832 No Marked Reduction Observed Over Time	No detectable Class I anti-HLA antibody at baseline MFI 3000 to <10000	Baseline MFI 3000 to <10000

C.

	Class I	Class II
Patient 0811 No Marked Reduction Observed Over Time	Baseline MFI ≥10000 	Baseline MFI ≥10000
Patient 0832 No Marked Reduction Observed Over Time	No detectable Class I anti-HLA antibody at baseline MFI ≥10000	No detectable Class II anti-HLA antibody at baseline MFI ≥10000

C, cycle; D, day; FUP, follow-up; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; WK, week.

Supplemental Figure 4. Representative images of mBCs HLA-sp B-cell fluorospot before and after treatment.

